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Abstract
Tumor cells that disseminate from the primary tumor and survive the vascular system can eventually extravasate across the
endothelium to metastasize at a secondary site. In this study, we developed a microfluidic system to mimic tumor cell
extravasation where cancer cells can transmigrate across an endothelial monolayer into a hydrogel that models the
extracellular space. The experimental protocol is optimized to ensure the formation of an intact endothelium prior to the
introduction of tumor cells and also to observe tumor cell extravasation by having a suitable tumor seeding density.
Extravasation is observed for 38.8% of the tumor cells in contact with the endothelium within 1 day after their introduction.
Permeability of the EC monolayer as measured by the diffusion of fluorescently-labeled dextran across the monolayer
increased 3.8 fold 24 hours after introducing tumor cells, suggesting that the presence of tumor cells increases endothelial
permeability. The percent of tumor cells extravasated remained nearly constant from1 to 3 days after tumor seeding,
indicating extravasation in our system generally occurs within the first 24 hours of tumor cell contact with the endothelium.
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Introduction
Tumor metastasis is the hallmark of malignant cancer and the
cause of 90% human cancer deaths [1,2]. Thus the real threat of
cancer is that malignant tumor cells are able to escape from the
primary site and form metastatic colonies in secondary sites.
During metastasis, epithelial cancer cells undergo epithelial-
mesenchymal transition (EMT), disperse from the primary tumor,
and intravasate into the vascular system. Cancer cells, once in the
circulation, are transported to a remote site where they can
extravasate from the vascular system into the surrounding tissue to
colonize at remote sites, completing the dissemination process
[3,4]. While there exists an enormous literature on oncogenic
transformation and emergence of the primary tumor, much less
research addresses issues related to metastasis [5]. There is little
doubt that a deeper understanding of cancer metastasis could lead
to novel therapeutic strategies targeting the invasion pathways and
improving cancer survival rates [6].
Extravasation is a vital step in cancer cell dissemination, which
enables successful establishment of a secondary metastasis. The
process of extravasation consists of: 1) transport via blood
circulation, 2) arrest adjacent to a vessel wall, and 3) transmigra-
tion across the endothelial monolayer into the secondary site [7].
For tumor cell arrest on vessel wall, two possible modes have been
proposed. One, proposed by Paget as the ‘‘seed and soil’’
hypothesis, is that tumors of different organs show unique patterns
of metastatic colonization to specific organs through site-selective
adhesion [8]. In a second mode, tumor cells become trapped in
small vessels due to size restriction as tumor cells tend be larger
than other circulating cells and can also aggregate with platelets
[9,10,11]. While both modes have been observed during
extravasation [3,12,13,14], it is still not clear which is dominant
or whether different tumor types preferentially exhibit a particular
type of arrest prior to transmigration. Furthermore, invasive
behavior of tumor cells depends on cross-talk between tumor and
host cells in a complex three dimensional (3D) microenvironment
[15]. Direct observation of tumor cell arrest on an endothelium
with controlled microenvironmental conditions would provide
useful insight into this crucial step of extravasation. Also the
establishment of secondary metastases at a distant organ after
transmigration requires tumor cell interaction with a diverse array
of extracellular matrix (ECM) components, such as collagen,
laminin and fibronectin [16]. However, the roles of microenvi-
ronmental cues and cytokine gradients within the tissue during the
process of extravasation are not well understood.
Conventional studies of extravasation rely primarily on tail-vein
injection of tumor cells with subsequent imaging and analysis
in vivo [17,18]. Although these in vivo experiments provide the most
physiologically representative conditions for extravasation, they
have limitations in studying tumor and vessel interactions as
videomicroscopy provides only limited visualization of the event,
and tightly-regulated parametric studies are not possible. In vitro
models offer solutions to these problems, which led to widespread
use of the Boyden chamber for simulating the invasion or
migration of cancer cells [19,20]. The relative simplicity of
operation is an advantage of this system, but there are limitations
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in using it for studying complex interactions between cancer cells
and the endothelium. The Boyden chamber has limited control
over the local microenvironment and less than optimal imaging
capabilities. In an attempt to address these needs, there has been a
growing interest using microfluidic technology since it provides a
simple yet effective means to investigate these phenomena under
tight control of the biochemical and biophysical environment
[21,22,23,24].
We have previously reported an in vitro microfluidic platform
that offers the capability to more realistically mimic the 3D in vivo
situation in a controlled environment while simultaneously
providing in situ imaging capabilities for visualization, thereby
enabling quantification of cell-cell and cell-matrix interactions
[25,26,27,28]. Moreover, the system enables parametric study of
multiple factors in controlled and repeatable conditions as well as
study with multiple cell types with an endothelial barrier
[26,29,30]. While no in vitro systems can fully replicate the in vivo
situation, microfluidics offers the opportunity to create organ-
specific microenvironments to explore the different metastatic
patterns of different cancer types in a regulated, and easily-
visualized model.
Microfluidic platforms of various designs have been previous
employed to study cell migration and tumor cell intravasation
[24,31]. In this paper, we used the established microfluidic system
to investigate the critical steps of cancer extravasation – tumor cell
adhesion to the endothelium, transmigration across the endothelial
monolayer, proliferation in remote tissues – and its consequences.
Our experimental platform mimics the tumor microenvironment,
allows for high resolution imaging of tumor cell extravasation and
early steps of colonization, thus enabling better quantification of
the critical metrics of cancer cell invasiveness.
Materials and Methods
Microfluidic System
In these studies we used a previously developed microfluidic
system consisting of three independently addressable media
channels, separated by chambers into which an ECM-mimicking
gel can be injected (Fig. 1a). Details of the design and the steps
required for fabrication of the systems in PDMS have been
described previously [25,28,30]. In brief, the microfluidics system
consists of molded PDMS (poly-dimethyl siloxane; Silgard 184;
Dow Chemical, MI) through which access ports are bored and
bonded to a cover glass to form a microfluidic channels. Channel
cross-sectional dimensions are 1 mm (width) by 120 mm (height).
The PDMS layer is formed from a patterned SU8 photoresist on a
silicon wafer using soft-lithography. To enhance matrix adhesion,
the PDMS channels are coated with a PDL (poly-D-lysine
hydrobromide; 1 mg/ml; Sigma-Aldrich, St. Louis, MO) solution.
Next, collagen type I (BD Biosciences, San Jose, CA, USA)
solution (2.0 mg/ml) with phosphate-buffered saline (PBS; Gibco)
and NaOH is injected into the gel regions of the device via 4
separate filling ports using a 10 ml pipette and incubated for
30 min to form a hydrogel, chosen to represent ECM in 3D space.
When the gel is polymerized, endothelial cell medium is
immediately pipetted into the channels to prevent dehydration
of the gel. Upon aspirating the medium, diluted MatrigelTM (BD
science) solution (3.0 mg/ml) is introduced into the cell channel
and the excess MatrigelTM solution is washed away 1 minute later
Figure 1. General schematic of the device. Microfluidic system consisting of three independently addressable media channels, separated by
chambers into which an ECM-mimicking gel can be injected (a). Figure 1b shows the inside view of the device with endothelial monolayer (blue)
covering the center channel. This channel acts as cell channel where both endothelial cells and cancer cells are introduced to form monolayer and
transmigrate respectively (b). The green region indicates the 3D space filled with collagen gel and the pink regions indicate the channel filled with
medium. Cancer cells which adhere to endothelial monolayer can extravasate into the collagen gel region as shown in (c).
doi:10.1371/journal.pone.0056910.g001
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using cold medium. 2D top and face views of the device are shown
in Fig. 1b–c to show how this microfluidic system is used to model
extravasation. Endothelial cells are first introduced to cover the
entire middle channel and later cancer cells are introduced so they
adhere to and transmigrate across the already formed endothelium
into the gel region. The middle channel acts as a cell channel
where both endothelial cells and cancer cells are introduced to
form a monolayer and transmigrate, respectively.
Cell Culture and Cell Selection
Human microvascular endothelial cells (hMVECs) were com-
mercially obtained (Lonza) and cultured in endothelial growth
medium (EGM-2MV, Lonza). Cells were cultured in standard
culture flasks and the medium was changed every two days until
seeding. During the seeding process, 40 ml of hMVEC suspension
at 26106 cells/ml was introduced into the prepared microfluidic
device. The cells were kept in a 37uC incubator for 1 hour to allow
the adhesion of cells to the collagen scaffold wall. All experiments
were conducted using hMVECs of passage 8 or lower. Human
mammary adenocarcinoma cells (MDA-MB-231) were chosen due
to their invasiveness and their ability to metastasize in vivo [32,33].
A GFP-expressing version of the MDA-MB-231 cell line (provided
by F. Gertler, MIT) enabled live-cell imaging via fluorescent
microscopy. Cancer cell lines were cultured in standard DMEM
media (Sigma) with 10% fetal bovine serum (Invitrogen) and
antibiotics. The human mammary epithelial cell line MCF-10A
(provided by Brugge Lab, Harvard Medical School) was cultured
as described previously [34]. Two days after endothelial cell
seeding, tumor cells were introduced into the same channel where
endothelial cells had formed a complete monolayer. Culture flasks
containing the tumor cells were first washed with PBS and the cells
were later trypsinized for 5 min to make the cell suspension in
cancer cell medium. For seeding, 40 ml of 50000 cells/ml tumor
cell suspension medium was placed in one side of the channel
reservoir and left to equilibrate. The tumor cell suspension
medium in the channel was removed 1 hour later and all channels
in the device were filled with endothelial cell culture medium.
Control experiment with MCF-10A was done following the exact
tumor cell seeding protocol. All cultures were kept in a humidified
incubator, which was maintained at 37uC and 5% CO2.
Permeability of Endothelial Monolayer
Upon formation of a complete endothelial monolayer by day 2,
the diffusive permeability was measured with fluorescently-labeled
dextrans in culture medium as shown in Fig. S1 (10 kDa cascade
blue and 70 kDa MW Texas red, Invitrogen). The endothelial
monolayers grown in our microfluidic system exhibited lower
diffusive permeability values for the smaller molecular weight
dextran confirm the presence of a size-selective endothelial barrier.
To characterize changes in permeability upon extravasation, we
used the 70 kDa dextran. Before introducing dextran into the
device, the endothelium was first examined using a phase contrast
microscope (Nikon, Tokyo, Japan) to confirm monolayer forma-
tion on both the top and the bottom of the channel by focusing at
different heights. All medium in the device reservoirs was aspirated
first and later re-filled with control medium in the side channels
whereas the cell-seeded middle channel was filled with fluorescent
dextran solution (10 mg/ml) in medium in the cell-seeded middle
channel. Precisely 110 ml was promptly added to each channel so
as to maintain equal pressures and thereby avoid convective flow
across the hydrogel. Devices were then placed in the incubator for
3 hours to reach steady state, fluorescent images of dextran
distributions were taken using an epi-fluorescent microscope
(Nikon TE300, Hamamatsu ORCA-ER camera) and processed
using OPENLAB 4.0.4 software. Images were later analyzed using
MATLAB to calculate fluorescence intensity across the monolay-
er. To determine the diffusional permeability, we calculated the
distribution of fluorescence intensity change as a function of
distance perpendicular to the plane of the endothelial layer. A
detailed procedure for measuring permeability has been described
previously [24,35,36,37]. Briefly, we used the equation P=D [dC/
dx]/DCec where P is the diffusive permeability (cm/s), dC/dx is
the gradient of the dextran concentration, DCec is the concentra-
tion difference across the monolayer, and D is diffusion coefficient
of dextran.
Immunofluorescent Staining and Image Acquisition
All cells in the device were washed with Phosphate Buffered
Saline (PBS) and later fixed with 4% paraformaldehyde for
15 min. After washing twice with PBS, cells were permeabilized
with 0.1% Triton-X 100 solution for 5 min and blocked with 5%
BSA solution for 5 h. VE-cadherin was labeled with rabbit
polyclonal antibody (polyclonal; Alexis Biochemical) at 1:100
dilution and subsequently applied fluorescently-labeled secondary
antibody. Cell nuclei were stained with DAPI (Invitrogen) at
1:1000 dilution. All images were obtained using a confocal
microscope (Leica) and processed with IMARIS software.
Metrics for Extravasation
Quantitative cell counting was performed after immunofluores-
cent staining. Confocal data were analyzed using IMARIS and its
tracking algorithms for selecting and counting for nuclei in the
specific region of interest (ROI). The ROI was the 3D gel region
between a PDMS post and the wall as seen in boxed area of Fig. 1b
that was selected during confocal imaging and contained both the
endothelial lining channel region as well as the collagen gel. ROIs
were selected such that edge effects associated with PDMS walls
and posts were avoided. The dimensions of the ROI were
250 mm6250 mm6120 mm (height) and each microfluidic device
contained total eight ROIs. While each ROIs were analyzed
individually, the extravasation percentage was measured per
device. As the tumor cells express GFP, cells with both green
and blue signal were counted to track the number of tumor cells.
Statistics
All values reported are averages of measurements from a
minimum of 4 devices, each with a minimum of 2 and maximum
of 8 ROIs with standard errors. The comparisons between
unpaired groups were assessed using unpaired Student’s t-test and
the nonparametric Mann-Whitney U statistic whereas paired
permeability measurements were assessed using a paired t-test.
Tumor seeding density statistics were obtained using one-way
ANOVA. Statistical significance was assumed for p,0.05. All tests
were performed with SigmaPlot v.12.
Results and Discussion
Modeling the Extravasation Process
Although there remains considerable uncertainty regarding the
critical, rate-limiting step in the formation of metastatic tumors,
the ability of circulating tumor cells (CTCs) to adhere to and
transmigrate across the endothelium at a remote site is certainly
essential. Numerous studies have addressed this issue, but the
challenges of constructing a meaningful in vitro testing platform has
been a strong impediment to improved understanding, and as
importantly, has posed a barrier to the identification of drugs that
could inhibit extravasation. Recent studies have begun to address
this need using advanced microfluidics [21,22,23], but each is has
In Vitro Model of Tumor Cell Extravasation
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its limitations. In the current model, we demonstrate the capability
of monitoring the entire process of extravasation. Our previous
studies in a similar system have demonstrated changes in
endothelial permeability are closely associated with intravasation
[24], so we sought to study similar changes that might occur
during extravasation. In addition, by tracking the cells over time,
we were able to explore the time-dependent behavior, an
important factor that impacts both the survival of the CTCs prior
Figure 2. Confirmation of endothelial monolayer integrity. The integrity of the endothelial monolayer was confirmed by both fluorescence
imaging of the dextran distribution and confocal microscopy of fixed and labeled cells. An intact endothelial monolayer gives rise to an abrupt
intensity drop between the channel and the gel region once the fluorescently-labeled dextran is introduced. Three hours after dextran injection, a
sharp drop in fluorescence intensity is seen across the endothelial layer demonstrating its function as a barrier to macromolecules (a). Fluorescence
intensity is quantified using Matlab (b). The dashed arrow in (a) the location and direction for the quantification.The intensity value drops to 15% of is
peak value due to the barrier effect. The endothelial monolayer is located near the 400 mm point on the plot (shown with dashed line). Samples fixed
on the third day after cell seeding and stained for VE-cadherin and nuclei (DAPI-blue) exhibit well-defined junctions with no apparent gaps in the
confluent monolayer (c). The confocal image shows the front view of the microfluidic device.
doi:10.1371/journal.pone.0056910.g002
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to extravasation as well as their ability to reconfigure the
immediate microenvironment prior to transmigration.
Confirmation of Endothelial Layer Integrity
The microfluidic system was designed to model tumor cell
extravasation where the tumor cells are introduced into a channel
lined with a confluent endothelial monolayer. Using phase contrast
microscopy, hMVECs were observed forming a confluent
monolayer on the microchannel surfaces and ECM-endothelial
channel interface two days after endothelial cell seeding. The
integrity of the endothelial monolayer was confirmed by both
fluorescence imaging of the dextran distribution and confocal
microscopy of fixed and labeled cells. An intact endothelial
monolayer gives rise to an abrupt intensity drop between the
channel and the gel region once the fluorescently-labeled dextran
is introduced, and persists over time as dextran slowly diffuses
across the monolayer into the gel (Fig. 2a–b). Samples fixed on the
third day after cell seeding and stained for VE-cadherin and nuclei
(DAPI-blue) exhibit well-defined junctions with no apparent gaps
in the confluent monolayer (Fig. 2c). Quantification and analysis of
fluorescence intensity yields values for the endothelial permeability
to a 70 kDa dextran (3.7060.59)?1026 cm/s, or roughly one order
of magnitude higher than published in vivo values but consistent
with previously reported values in in vitro systems [35,38]. The
higher values of permeability may be due to a variety of factors
present in vivo but missing from the in vitro model. For example, it
is well known that the presence of pericytes helps to establish the
low permeability of vessels in vivo [38]. In view of our previous
work demonstrating that increased permeability correlates with
increased rates of intravasation [24], to the extent that cells use
similar mechanisms for extravasation as intravasation, the present
Figure 3. Optimization of tumor cell seeding density. The tumor cell seeding density was optimized to have only a limited number of tumor
cells in ROI while maintaining as many experimental ROIs as possible that contain at least one tumor cell so tumor cell events can be observed.
Histograms of number of total tumor cells present in each ROI (250 mm6250 mm6120 mm) show different trends in distribution of tumor cells for
three different tumor seeding densities: 20,000 cells/ml, 50,000 cells/ml, and 200,000 cells/ml (a). The average value and the histogram can be used
for choosing the optimal tumor seeding condition (b). Seeding density of 50,000 cells/ml was chosen as a compromise between mimicking the low
number of tumor cells of the in vivo of extravasation condition and increasing the chance to have at least one tumor cell to analyze in any given ROI.
The statistical significance was tested with one way ANOVA (p,0.05).
doi:10.1371/journal.pone.0056910.g003
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extravasation rates may be viewed as being biased toward higher
values than physiologic.
Optimization of Tumor Cell Seeding
From clinical data, the number of tumor cells that have
intravasated and travel in circulation has been measured to be less
than ,100 in 7.5 mL of blood on average [39,40]. For the
purpose of these experiments, we chose to use a seeding density
which was neither so low we were unable to view a significant
number of extravasation events in a reasonable number of
experiments, nor so high the tumor cells were densely packed at
the endothelial surface. This latter situation might lead to tumor
cell interactions that poorly represent the situation in vivo. Hence,
in this experiment, the tumor cell seeding density was optimized to
have only a limited number of tumor cells in the ROI while
maintaining as many experimental ROIs as possible that contain
at least one tumor cell to facilitate extravasation event observation.
Histograms of number of total tumor cells present in each ROI
show different trends in distribution of tumor cells for three
different tumor seeding densities: 20,000 cells/ml, 50,000 cells/ml,
and 200,000 cells/ml (Fig. 3a). Although the smallest tumor
seeding density results in the smallest average number of tumor
cells in each ROI as shown in Fig. 3b, this is due to having ROIs
without any tumor cells 55% of the time. The average value and
the histogram can be used for choosing the optimal tumor seeding
condition and a seeding density of 50,000 cells/ml was chosen as a
compromise between mimicking the low number of tumor cells of
the in vivo of extravasation condition and increasing the chance to
have at least one tumor cell to analyze in any given ROI.
Extravasation
Tumor cells that disseminate from the primary tumor and
survive the vascular system can eventually transmigrate across the
endothelium to recolonize at a secondary tumor site. With the
microfluidic system developed, we can mimic the extravasation
step where tumor cells can transmigrate across an endothelial
monolayer into a hydrogel which models the extracellular space of
a secondary tumor site. The extravasation event is observed in
devices that are fixed 1 day after tumor cells are introduced, and
direct quantification of the number of extravasated cells provides a
metric of extravasation. The region of interest (ROI) is captured in
one confocal image scan and shows one cancer cell, labeled green,
that has transmigrated across the endothelium,denoted by VE-
cadherin staining in red, and extravasated into the gel region
(Fig. 4a). Surface views of the confocal scan from other samples
show three different possible locations of tumor cells 1 day after
the seeding: 1) extravasated and in gel, 2) adhered and located on
Figure 4. Observation of extravasation and permeability of
endothelium. The extravasation event is observed in a sample, which
is fixed 1 day after tumor cells are introduced. The region of interest is
captured in one confocal image scan and shows one cancer cell (green)
that has transmigrated across the endothelium (denoted by VE-
cadherin staining in red) and extravasated into the gel region (a). The
surface view of the confocal scan shows three different possible
locations of tumor cells: 1) extravasated and in gel, 2) adhered and on
endothelium adjacent to gel region, and 3) in channel not near the gel.
The sectional view of the same confocal scan confirms the different
location of the tumor cells (b). The graph shows how many tumor cells
have extravasated (dot) among the total tumor cells present (bar) for
each region of interest analyzed (c). The tumor cells are categorized as
extravasated only when the tumor cells have clearly passed the
endothelial monolayer into the gel region. The permeability of
endothelial monolayer changes significantly with addition of tumor
cells (d). Fluorescently-labeled dextran was introduced on day 3 after
endothelial seeding to measure the permeability before tumor and
again to same samples on day 4 to see the after tumor seeding effects.
The tumor cells are introduced on day 3 after day 3 permeability
measurements are taken. The statistical significance was tested with
paired t-test (p,0.05).
doi:10.1371/journal.pone.0056910.g004
In Vitro Model of Tumor Cell Extravasation
PLOS ONE | www.plosone.org 6 February 2013 | Volume 8 | Issue 2 | e56910
endothelium adjacent to gel region, and 3) in the channel not near
the gel (Fig. 4b). The surface and sectional views of the device
shown in Fig. 4b. All three scenarios of where tumor cells could be
are observed here. There are cases where all tumor cells present in
the ROI extravasated as well as cases where none of the tumor
cells crossed the endothelium. However, it is more common to find
regions that contain both extravasated and non-extravasated cells
as in Fig. 4b. This is seen quantitatively in Fig. 4c where 51% of
ROIs exhibited tumor cells with contrasting fate. The graph shows
how many tumor cells have extravasated, as shown by dots, among
the total tumor cells present in the each region of interest. The
tumor cells are categorized as having extravasated only when they
have clearly passed the endothelial monolayer into the gel region.
Measuring permeability of the endothelium is one method for
quantifying the quality of endothelial monolayer. In addition, the
permeability serves as a metric to quantify the change in
endothelium when tumor cells are added to the system and
interact via physical attachment to the endothelial surface.
Leakiness of the vessel with or without tumor cells provides a
possible explanation for events leading to cancer extravasation in
that signaling by the tumor CTCs could impair barrier function.
Alternatively, the increase in permeability could be a result of
tumor cell transmigration. From the present experiments, it is not
possible to distinguish between these two scenarios. In this
experiment, the permeability changed significantly with addition
of tumor cells compared to the permeability change occurring
during the same 24 h period when no tumor cells are added
(Fig. 4d). Fluorescently-labeled dextran was introduced on day 3
after endothelial cells were seeded to measure the permeability
before introducing tumor cells. Images were taken 3 hours after
Figure 5. Beyond extravasation. The tumor cell extravasation is observed for up to 3 days after tumor cell seeding and compared to the ones
fixed and analyzed on day 1. The total number of tumor cells present in region of interest (ROI) increases significantly from 8 cells on day 1 to 13.5
cells on day 3 while the tumor seeding density as well as other experimental condition remained the same between devices (a). The total number of
tumor cells are further subdivided into 2 groups depending on their location, either 1) extravasated and in the gel or 2) adherent to the endothelium
adjacent to gel (b). 72% of ROIs exhibited at least 1 extravasated cancer cell (denoted % extravasation occurrence) by day 1 after introducing tumor
cells, and 79% of ROIs included extravasation event by day 3, which the difference is not significant (c). The images show number of tumor cell
increase (d). The phase contrast image shows the top view of the region of interest on day 1 after tumor seeding. The tumor cells (green) have
proliferated from day 1 to day 3 (shown by arrows). The confocal image shows both the tumor cells and endothelium lining. All images are from the
same ROI (VE-cadherin: red, nucleus: DAPI-blue, tumor cell: GFP-green).
doi:10.1371/journal.pone.0056910.g005
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dextran insertion in order to achieve a quasi-steady state. Tumor
cells are introduced immediately after the permeability measure-
ments are taken. 24 hours later, fluorescently-labeled dextran was
again introduced to measure the permeability after tumor cell –
endothelial cell interactions. The initial permeability value was
(3.7060.59)?1026 cm/s and the tumor seeding increased endo-
thelial permeability to (14.262.6)?1026 cm/s (p,0.05) whereas
there was no significant change in the control ((6.061.1)?1026 to
(6.461.9)?1026 cm/s) over the same 24 hour period.
As a control, we measured the change in endothelial perme-
ability and extravasation rates of a normal epithelial cell line,
MCF-10A, in our microfluidic system. While extravasation was
observed for 38.867.9% of the tumor cells in contact with the
endothelium 1 day after seeding, the corresponding rate of MCF-
10A extravasation across the endothelium was lower, 23.864.7%,
although not significantly different. Addition of MCF-10A also
induced a 2-fold increase in permeability of endothelium from
(5.7860.47)?1026 to (11.8862.15)?1026 cm/s (p,0.05) as shown
in Fig. S2. This increase is smaller than the permeability increase
obtained after the addition of MDA-MB-231 (3.8-fold). Therefore,
the MDA-MB-231 cells show an increased tendency to extravasate
and compromise endothelial barrier function compared with
normal epithelial cells. These results show that our microfluidic
system is capable of detecting differences among different
epithelial cells lines and our results are consistent with extrava-
sation studies in a transwell assay [41].
The change in permeability of endothelium is regulated by VE-
cadherin expression through the Src pathway, and the studies of
in vivo models have shown that disruption of endothelial barrier
function enhanced extravasation efficiency [42]. Several mecha-
nisms exist which could explain changes in permeability due to
tumor cell interactions; the permeability increase may also be due
to tumor cells locally disrupting endothelial monolayer by contact
[43,44,45] or through secretion of chemical factors which then
compromises the endothelial barrier function [46], but more
investigation is needed for clear identification of the cause of the
permeability increases.
Beyond Extravasation
Tumor cells are observed for up to 3 days after tumor cell
seeding and compared to tumor cells on day 1. Average of total
number of tumor cells present in ROI increases significantly from
7.961.6 cells on day 1 to 13.461.5 cells on day 3 while all
experimental conditions including the tumor seeding density
remained the same (Fig. 5a). This significant increase in number of
tumor cells demonstrates proliferation from day 1 to day 3 overall.
The total number of tumor cells are further subdivided in Fig. 5b
into 2 subgroups depending on their location, either 1) extrava-
sated and in the gel or 2) adherent to the endothelium adjacent to
gel. The number of tumor cells per ROI in the gel increased from
1.960.4 cells on day 1 to 6.161.7 cells on day 3 while the cells on
endothelium changed from 4 cells on day 1 to 7 cells on day 3.
This increase in tumor cell number from day 1 to day 3 for the
extravasated cells could be due to either more cells extravasting
over the extra 2 day period, to proliferation, or both. Noting,
however, that the percentages of ROIs containing extravasated
cells event did not show a significant change for day 1 and day 3
(72% of ROIs exhibited at least 1 extravasated cancer cell by day 1
after introducing tumor cells, and 79% of ROIs included
extravasation event by day 3) (Fig. 5c), and assuming the
proliferation rates are similar to both populations, this suggests
most extravasation events occur within the first day the tumor cells
are introduced. This observation is similar in terms of time scale
for extravasation seen in vivo [17,47].
Conclusions
Tumor cells that disseminate from the primary tumor and
intravasate into the circulatory system are transported throughout
the body. By adhesion to the endothelial wall or plugging in a
small capillary, the cells that survive can transmigrate across the
endothelial barrier, thus providing a potential nucleating site for
metastasis. Our microfluidic platform was applied to study the
extravasation of a breast cancer cell line (MDA-MB-231) and their
subsequent proliferation in collagen gel, which mimics the 3D
nature of the extracellular space. Although microfluidics has
limitations in replicating true in vivo condition, the system
presented here enables a tightly-regulated and well-visualized
study of cancer cell extravasation. Using this assay, we have
cultured and sustained an endothelial monolayer spanning the
entire surface of a microchannel and hydrogel surface, and
introduced tumor cells to observe extravasation. We have also
quantified the permeability of the endothelial monolayer and
showed that endothelial barrier integrity is compromised by the
tumor cells. The average number of tumor cells in ROIs increased
between day 1 and day 3 after tumor cell seeding while the
percentage of ROIs with extravasated cells did not change
significantly. These results suggest that extravasation in our system
occurs predominantly within the first 24 hours of tumor cell
introduction and that proliferation can continue both prior to and
after extravasation.
Supporting Information
Figure S1 Size selective permeability values of the
endothelial monolayer are shown by measurements
with10 kDa and 70 kDa fluorescent dextrans. The smaller
sized dextran has a higher permeability value (p,0.05).
(TIF)
Figure S2 Permeability of the endothelium was mea-
sured using fluorescently-labeled dextran to investigate
the effect of adding the non-tumorigenic MCF-10A cells
(p,0.05).
(TIF)
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